Head and Neck Neoplasms
📧 Sign up to get email alerts when something new happens for Head and Neck Neoplasms.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2025-10-28Clinical Trial Update: Online Peri-operative Education Program for Patients Undergoing Major Head & Neck Surgery [NA]
The clinical trial evaluating an online peri-operative education program for patients undergoing major head and neck surgery has been withdr…
-
CLINICAL_TRIALS withdrawal · 2022-07-13Clinical Trial Update: Levothyroxine Treatment for Subclinical Hypothyroidism After Head and Neck Surgery [Phase 2, Phase 3]
Clinical trial for levothyroxine in subclinical hypothyroidism after head and neck surgery was withdrawn.
-
EMA withdrawal · 2022-05-20EMA Withdrawn: Docetaxel Zentiva (previously Docetaxel Winthrop) (docetaxel) — Zentiva k.s.
The EMA has withdrawn Docetaxel Zentiva (docetaxel) from the market. The therapeutic areas formerly associated include head and neck neoplas…
-
EMA withdrawal · 2021-12-14EMA Withdrawn: Docetaxel Teva (docetaxel) — Teva B.V.
The EMA has withdrawn Docetaxel Teva, an injectable chemotherapy containing docetaxel, from the European market.
-
EMA withdrawal · 2019-10-15EMA Withdrawn: Taxespira (previously Docetaxel Hospira UK Limited ) (docetaxel trihydrate) — Hospira UK Limited
The EMA withdrew Taxespira (docetaxel trihydrate) from the market for multiple cancer indications including stomach, prostate, breast, head …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2017-11-14Clinical Trial Update: An Imaging Study in Patients With Thyroid Cancer or Head and Neck Cancer With Pertechnetate Made in a Cyclotron (C-PERT) [Phase 2]
A Phase 2 imaging trial using cyclotron-produced pertechnetate (C-PERT) in patients with thyroid neoplasms or head and neck neoplasms has be…
-
EMA withdrawal · 2016-09-29EMA Application withdrawn: Docetaxel SUN — Sun Pharmaceutical Industries Europe B.V.
The EMA withdrew the application for Docetaxel SUN by Sun Pharmaceutical Industries Europe B.V. for multiple cancer indications.
-
EMA withdrawal · 2015-03-12EMA Lapsed: Docetaxel Mylan (docetaxel) — Mylan S.A.S.
EMA status shows Docetaxel Mylan has lapsed; related indications include head and neck neoplasms, non-small cell lung carcinoma, adenocarcin…
-
EMA withdrawal · 2010-03-26EMA Application withdrawn: Docetaxel Mylan (docetaxel) — Mylan S.A.S.
Withdrawal of the EMA application for Docetaxel Mylan (docetaxel) by Mylan S.A.S., affecting multiple solid tumor indications including non-…
-
EMA withdrawal · 2009-07-23EMA Application withdrawn: Contusugene Ladenovec Gendux — Gendux Molecular Limited
The EMA withdrawal of the application for Contusugene Ladenovec Gendux by Gendux Molecular Limited.